BianoScience GmbH Information

We founded BianoScience as a Spin-off from the Friedrich-Schiller-University of Jena, Germany, in 2011 as a privately owned biotech company. Our focus has been on oligonucleotides ever since. In parallel, we developed chiRNA, an therapeutic RNA prodrug platform. chiRNA consists of a chimeric RNA deactivated by a peptide cap. Disease specific proteases cleaving off the peptide activate the RNA selectively in diseased tissue or cells. Applications of the chiRNA platform include anticancer and antiviral theapies. The platform development was supported by the Gründungsoffensive Biotechnologie (GO-Bio) from the German Research Ministery. Today BianoScience offers the chiRNA platform technology is for collaborative development or licensing in specific areas or applications. During the five years of existence, BianoScience built an extensive portfolio of processes and technologies for high purity and high quality synthesis, labelling, in vitro and tissue analytics of nucleotide based molecules. We offer this know-how as a service to the academic and biotech community - to You. In 2016 we moved the BianoScience labs from Jena to Gera where we set up a GMP service facility for nucleotide based compound synthesis.